The Oxford Clinical Trials Research Unit (OCTRU) has integrated several trials groups from different therapeutic areas into a single Clinical Trials Unit (CTU). We are a fully registered CTU and lead and co-ordinate strategy, operations and systems across all of the trial groups.
Our scope is to design, conduct and report trials (across all phases) in surgery, musculoskeletal sciences, rheumatology and oncology.
We focus on development pathways and the evaluation of new health technologies in:
- surgery and interventional procedures (including anaesthetics, surgical procedures, pre- and post-surgical care)
- trauma, rehabilitation and conservative management
- pharmaceuticals, particularly in oncology
- the management of inflammation
- biomarkers to refine treatment strategies.
OCTRU has six therapeutic areas of expertise - all located in Oxford with leading researchers heading each theme.
- Critical Care, Trauma and Rehabilitation Trials Group
- Oncology Clinical Trials Office (OCTO)
- Surgical Intervention Trials Unit (SITU)
As part of OCTRU’s goal to ensure that clinical trials are designed and executed to the highest methodological and ethical standards, we participate in, and lead, methodological research of relevance to clinical trials.
This also ensures we gain and retain a position of leadership in the field, and are recognised internationally as a focus for high quality clinical trial design, conduct and reporting.
We work closely with the Centre for Statistics in Medicine (CSM), which is co-located with the Unit, where statisticians are involved in a number of clinical trials with clinicians and other health care researchers in Oxford and further afield.
CSM also carries out methodological research relating to the design, conduct and reporting of studies of diagnosis, prognosis, and clinical trials and hosts the EQUATOR initiative.
At OCTRU we collaborate with a number of world class methodologists. Individuals within the OCTRU team also play a lead role in a number of international initiatives. Read more here.